CTX CRC

CTx is governed by an independent skills-based Board and led by a highly experienced Management team. The collaborative research and business model allows innovative approaches to drug discovery as well as commercialisation of the research pipeline. The major focus for their drug discovery is early intervention in the metastatic cascade. With around 90% of cancer deaths resulting from progressive metastatic disease, it is imperative to move their attention to this arena and away from targeting ... advanced cancer where only limited benefits have been attained to date. They bring this focus to not only common adult cancers, but also to the somewhat neglected area of new drugs for children with cancer. To help us extend our reach in this area they have been joined in the partnership by Australia’s leading research institute for children’s cancerMore